Heat Biologics (HTBX) Shares Hit on Adverse HS-410 Combo Phase 2 Data in Invasive Bladder Cancer
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Heat Biologics (Nasdaq: HTBX) shares are getting hit early Thursday after the company announced that it presented topline data from its 94-patient Phase II trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), or as a monotherapy, for the treatment of non-muscle invasive bladder cancer..
In part, the news release read: "... these responses did not translate into clinical outcomes, and there was no statistically significant difference in the primary endpoint (proportion of recurrence-free survival at one year) between the vaccine and placebo arms of the trial."
In early trading, Heat Biologics shares are down over 58 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roth Capital Affirms Heat Biologics (HTBX) at 'Buy' Following HS-110 Combo Data
- Interpace Diagnostics (IDXG) Halted on LUDP Following 196% Surge
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!